Resistance to farnesyltransferase inhibitors in Bcr/Abl sorted by
relevance

Admin08.09.2021

Resistance to farnesyltransferase inhibitors in Bcr/Abl

308
Admin20.08.2021

Increased resistance to a farnesyltransferase inhibitor by

Admin15.09.2021

CML stem cells are resistant to BCR-ABL kinase inhibitor

2707
Admin06.08.2021

The coupleable analogues of the BCR-ABL inhibitors retain

8108
Admin21.09.2021

Flying under the radar: the new wave of BCR-ABL inhibitors

3401
Admin17.09.2021

Figure 1 from Second generation inhibitors of BCR-ABL for

39010
Admin17.09.2021

Rapid induction of resistance to BCR-ABL kinase inhibitors

5908
Admin26.07.2021

Figure 1 from BCR-ABL kinase domain mutation analysis in

8103
Admin22.08.2021

Characteristics of imatinib-resistant patients according

4101
Admin04.08.2021

The Growing Arsenal of ATP-Competitive and Allosteric

2702
Admin20.07.2021

Targeting the BCR-ABL Signaling Pathway in Therapy

4406
Admin13.08.2021

A farnesyltransferase inhibitor increases survival of mice

2803
Admin11.09.2021

Figure 1 from Mechanisms of Resistance to ABL Kinase

1601
Admin21.09.2021

Leukemia Fighter! (CML); I Am Dancing and Traveling My Way

6306
Admin01.08.2021

BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary

1204
Admin09.09.2021

STI571: an inhibitor of the BCR-ABL tyrosine kinase for

4200
Admin21.07.2021

Resistance to farnesyltransferase inhibitors in Bcr/Abl

9401
Admin08.08.2021

Inhibitors of Bcr-abl breaking new ground again

1801
Admin24.07.2021

(PDF) Combination treatment of imatinib-sensitive and

Admin24.09.2021

Past, present, and future of Bcr-Abl inhibitors: from

9805
Admin26.08.2021

(PDF) Bcr-Abl-Independent Imatinib-Resistant K562 Cells

403